FORGOT YOUR DETAILS?

How to build a

blockbuster

exclusive breakfast panel

Tuesday, jan 8th 2019
7:00 - 8:30a

grand hyatt union square
345 stockton street, san francisco

Getting a drug through the clinic and on to an FDA approval is a huge accomplishment. But the big question facing developers now is: How do you build a blockbuster? 

- What are the elements you need to consider in trial designs? 
- Are there better, more economical ways to achieve a major market impact?
- What role does the FDA play in advancing innovation faster?

We’ll offer a panel of experts — people who have done that and been there — as we consider the future of drug development and how current trends will dictate the fate of our industry.

Sandra Horning

CMO
Genentech
PANELIST

John Reed

EVP, Global Head of R&D
Sanofi
PANELIST

David Chang

President & CEO
Allogene
PANELIST

Andrew Plump

CSMO
Takeda
PANELIST

John Carroll

Founder & Editor
Endpoints News
MODERATOR

sponsored by

Stephen R. Davis

CEO
ACADIA
SPEAKER

SPONSORSHIP PACKAGES AVAILABLE

Mike Peck - VP, Partnerships at Endpoints News - mike@endpointsnews.com

panelists

Sandra Horning

CMO
Genentech

Sandra J. Horning, MD, FACP, FASCO, was appointed Chief Medical Officer and head of Global Product Development in January 2014. She oversees late stage clinical development and co-chairs the Late Stage Portfolio Committee.

Sandra joined Roche in late 2009 as senior vice president, global head of clinical oncology and hematology product development. She is an Emerita Professor of Medicine (Oncology and Blood and Bone Marrow Transplantation) at Stanford University School of Medicine where she served as a tenured professor, practicing oncologist and investigator, and held multiple leadership positions including Vice-Chair of the Department of Medicine prior to joining Roche/Genentech.

Sandra has authored 300 peer-reviewed journal articles, book chapters, reviews and editorials, and has served on the editorial boards of multiple peer-reviewed medical journals. She was named a Best Doctor in America consecutively from 1992-2008 and served as Chairman of the Eastern Cooperative Oncology Group lymphoma committee and 2005-6 President of the American Society of Clinical Oncology.

Sandra received Bachelor of Arts and Doctor of Medicine degrees at the University of Iowa and completed post-doctoral training in internal medicine at the University of Rochester and in medical oncology at Stanford University.

John Reed

EVP, Global Head of R&D
Sanofi

Dr. John Reed is Executive Vice President, Global Head of Research & Development, of Sanofi.

Dr. Reed joined Sanofi in July 2018 from Roche, where he most recently served as Global Head of Roche Pharmaceutical Research & Early Development since 2013. He was responsible for directing research and early development activities through Phase 2b proof-of-concept across all therapeutic areas, including oncology, immunology, rare diseases, neuroscience, ophthalmology and infectious diseases.

Prior to Roche, Dr. Reed was the President and CEO of the Sanford-Burnham Medical Research Institute, where he began his career. Dr. Reed held multiple positions of increasing responsibility at Sanford-Burnham, which is one of the best known biomedical research institutes in the U.S. Those positions included Program Director of the NCI-designated Cancer Center, Scientific Director, and Director of the Cancer Center until Dr. Reed was ultimately being appointed to President and CEO in 2002.

Dr. Reed holds a B.A in chemistry from the University of Virginia, Charlottesville, and a M.D. and Ph.D. from the University of Pennsylvania School of Medicine.

David Chang

President & CEO
Allogene

David Chang, MD, PhD, is the President, Chief Executive Officer and Co-Founder of Allogene. He previously served as Executive Vice President, Research & Development, and Chief Medical Officer of Kite, a Gilead Company. He has an industry-leading track record of innovation in the field of oncology drug development, including the development of Yescarta™ (axicabtagene ciloleucel), the first CAR T therapy approved for non-Hodgkin lymphoma.

 

From 2002 to 2014, he held senior leadership roles at Amgen, including Vice President of Global Development and Head of Hematology-Oncology. During this time, David spearheaded personalized therapy strategies underlying the success of Vectibix® (panitumumab). He also provided therapeutic area leadership to pivotal programs for Blincyto® (blinatumomab), a bispecific T cell engager antibody in acute lymphocytic leukemia and for IMLYGIC™ (talimogene laherparepvec), a first-of-its-kind oncolytic immunotherapy in melanoma. Prior to joining Amgen, David held dual appointments as Associate Professor of Medicine and of Microbiology, Immunology and Molecular Genetics at the David Geffen School of Medicine at the University of California, Los Angeles. He obtained a B.S. in biology from the Massachusetts Institute of Technology and M.D. and Ph.D. degrees from Stanford University.

 

David completed an internship and residency in internal medicine at Brigham and Women’s Hospital and a fellowship in medical oncology at Dana-Farber Cancer Institute at Harvard Medical School, where he was a Howard Hughes Medical Institute postdoctoral fellow. David serves as a Director at A2 Biotherapeutics and Peloton Biotherapeutics, and a Venture Partner at Vida Ventures.

Andrew Plump

Chief Medical and Scientific Officer
Takeda

In 2015, Andrew Plump, M.D., Ph.D., joined Takeda as Chief Medical and Scientific Officer (CMSO). Dr. Plump also serves as a member of Takeda’s Executive Team and of the company’s Board of Directors. In his position, he leads Takeda’s global Research & Development organization, where he provides strategic direction and oversight.

Dr. Plump brings an unwavering focus on patients and a deep commitment to innovation and positive change in the healthcare industry. To continue and accelerate Takeda’s R&D successes, he leads an organization that focuses on people and partnerships, modality diversification, and translational medicine and genomics.

Prior to Takeda, Dr. Plump served as Senior Vice President, Research & Translational Medicine, Deputy to the President of R&D at Sanofi, where he was responsible for global research and translational medicine across all therapeutic areas.

Dr. Plump also spent more than 10 years at Merck in a Clinical Pharmacology group, working on programs in neurodegeneration, immunology, metabolism and infectious diseases. Following additional roles focusing on early development, genomics and biomarkers, particularly in cardiovascular and metabolism, he assumed the position of Vice President, Worldwide Cardiovascular (CV) Research Head. In this role, he had direct responsibility for preclinical development and research teams, and a leadership role in the end-to-end activities of the Merck cardiovascular portfolio. Together with his team, he helped discover and support a pipeline of novel therapies in atherosclerosis, vascular diseases and thrombosis.

Dr. Plump received his medical degree from the University of California, San Francisco (UCSF), his doctorate in cardiovascular genetics with Dr. Jan Breslow from the Rockefeller University, and his bachelor’s degree from the Massachusetts Institute of Technology in the U.S. He completed a residency in Internal Medicine and a fellowship in Medical Genetics at UCSF. Following his clinical training, Dr. Plump continued his scientific training in neuroscience as a Howard Hughes and Stanley J. Sarnoff postdoctoral fellow, with Dr. Marc Tessier-Lavigne, concurrently assuming faculty responsibilities as an Adjunct Clinical Instructor in the Department of Medical Genetics.

moderator

John Carroll

Founder & Editor
Endpoints News

John D. Carroll is a biotech analyst and writer with decades of prize-winning experience in journalism.

A co-founder of Endpoints News, he has covered biopharma for the past 15 years. Aside from his previous daily industry coverage at FierceBiotech, where he was named editor in 2003, leaving in 2016, Carroll has been a regular speaker at biotech events around the globe. He’s been quoted by The New York Times, The New Yorker, Financial Times, The Times of London and more. He’s also keynoted at biotech gatherings around the world and addressed student audiences at MIT and Harvard.

Carroll has contributed stories from Central America and Ireland to the Dallas Morning News and Time and wrote for the Houston Press. He spent 6 years as editor and publisher of the Dallas Business Journal, was publisher of Texas Businessand early in his career was part of a Pulitzer Prize-winning team of reporters and editors at the Kansas City Star & Times.

speaker

Stephen R. Davis

Chief Executive Officer
ACADIA

Stephen R. Davis is Chief Executive Officer and a member of ACADIA's Board. Mr. Davis joined ACADIA in July 2014 as Executive Vice President, Chief Financial Officer and Chief Business Officer. He was appointed Interim Chief Executive Officer in March 2015 and President and Chief Executive Officer in September 2015.

Mr. Davis brings over 20 years of executive-level experience in the pharmaceutical industry and more than 20 years of experience on the boards of directors of publicly held biopharmaceutical companies. Previously, Mr. Davis served as Executive Vice President and Chief Operating Officer at Heron Therapeutics, Inc., Executive Vice President and Chief Operating Officer at Ardea Biosciences, Inc., and in numerous executive roles at Neurogen Corporation, including Chief Executive Officer. Mr. Davis currently serves on the Board of Directors of Bellicum Pharmaceuticals, Inc. He also recently served on the boards of directors of Synageva BioPharma Corp., Heron Therapeutics, and Furiex Pharmaceuticals, Inc.

Early in his career, Mr. Davis practiced as a Certified Public Accountant with a major accounting firm and as a corporate and securities attorney with a Wall Street law firm. Mr. Davis received his Bachelor of Science degree in Accounting from Southern Nazarene University and a J.D. from Vanderbilt University.

© 2018 Endpoints Company

TOP